TY - JOUR
AU - Kessler, Lukas
AU - Schwaning, Felix
AU - Metzenmacher, Martin
AU - Pabst, Kim M
AU - Opitz, Marcel
AU - Wiesweg, Marcel
AU - Aigner, Clemens
AU - Ploenes, Till
AU - Boeloekbas, Servet
AU - Doerr, Fabian
AU - Stuschke, Martin
AU - Umutlu, Lale
AU - Nader, Michael
AU - Theegarten, Dirk
AU - Eberhardt, Wilfried E
AU - Schuler, Martin
AU - Herrmann, Ken
AU - Fendler, Wolfgang P
AU - Kersting, David
AU - Hautzel, Hubertus
TI - Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma.
JO - Journal of nuclear medicine
VL - nn
SN - 0097-9058
CY - New York, NY
PB - Soc.
M1 - DKFZ-2026-00070
SP - nn
PY - 2026
N1 - #DKTKZFB9# / #NCTZFB26# / epub
AB - High expression of fibroblast activation protein (FAP) has been associated with inferior survival in several tumor entities. Novel 68Ga-radiolabeled FAP inhibitors (68Ga-FAPIs) allow noninvasive measurement of FAP, which enables the development of prognostic imaging parameters from 68Ga-FAPI PET/CT. In this study, we compared the prognostic value of 68Ga-FAPI-46 with 18F-FDG PET in a cohort of patients with malignant pleural mesothelioma from the FAPI PET observational trial (NCT04571086). Methods: Between May 2020 and January 2024, 49 patients with suspected or proven malignant mesothelioma were recruited, 39 of whom were eligible for data analysis. All patients underwent 68Ga-FAPI-46 and 18F-FDG PET/CT less than 4 wk apart. Tumor burden was measured semiautomatically, and SUVmax, SUVmean, and volumetric parameters (metabolic tumor volume [MTV], total lesion glycolysis/total lesion fibroblast activation, and total tumor SUV) were calculated. The FAP immunoreactive score (IRS) was calculated for tumor samples from a subset of patients (n = 19). Overall survival and progression-free survival were assessed per revised mRECIST (version 1.1). Survival analyses were performed with univariate and multivariate Cox regression and with Kaplan-Meier curves for clinical and imaging parameters, stratified by median. Results: Univariate analysis showed significant survival differences for all volumetric parameters for 68Ga-FAPI-46 and 18F-FDG (e.g., 68Ga-FAPI-46 MTV, 262 d vs. 737 d; P = 0.008 vs. 18F-FDG MTV, 336 d vs. 760 d; P = 0.012). Multivariate analysis revealed that MTV was an independent prognostic marker for 68Ga-FAPI-46 (hazard ratio, 4.44; 95
KW - FAPI (Other)
KW - cancer imaging (Other)
KW - fibroblast activation protein (Other)
KW - mesothelioma (Other)
KW - theranostic (Other)
LB - PUB:(DE-HGF)16
C6 - pmid:41506801
DO - DOI:10.2967/jnumed.125.270906
UR - https://inrepo02.dkfz.de/record/307575
ER -